Sponsor: Eli Lilly and Company · sponsor also appears in the payment records
Disclosed research payments
$1,252,245
Named PIs
5
- NEHAL LAKHANI: $417,080
- BHAVANA POTHURI: $294,847
- CLAIRE FRIEDMAN: $201,294
Breast Cancer (HR+/HER2-): drug payment transparency
For hormone-receptor-positive, HER2-negative metastatic breast cancer, the CDK4/6 inhibitor class has three close substitutes with overlapping indications. In the adjuvant setting, only abemaciclib is currently FDA-approved in the U.S. for high-risk early breast cancer — but in metastatic disease all three are options, with real differences in tolerability, dosing schedules, and clinical-trial performance.
Data from CMS Open Payments (2023–2024) · last checked
The drugs in question
These are the close-substitute branded therapies your oncologist may choose among for breast cancer (hr+/her2-). Generic and biosimilar options may also be available depending on line of therapy.
CDK4/6 inhibitors
- Ibrance (palbociclib) — Pfizer
- Kisqali (ribociclib) — Novartis
- Verzenio (abemaciclib) — Eli Lilly
Selective estrogen receptor degraders (SERDs)
- Faslodex / generic (fulvestrant) — AstraZeneca / multiple
- Orserdu (elacestrant) — Stemline Therapeutics (Menarini)
PI3K / AKT / mTOR pathway inhibitors
- Piqray (alpelisib) — Novartis
- Truqap (capivasertib) — AstraZeneca
- Afinitor / generic (everolimus) — Novartis / multiple
Antibody-drug conjugates (for later-line HER2-low)
- Enhertu (trastuzumab deruxtecan) — AstraZeneca / Daiichi Sankyo
- Trodelvy (sacituzumab govitecan) — Gilead
Top paying manufacturers to oncologists in our index
Across all oncologists in our index (all cancer types), these are the companies making these breast cancer (hr+/her2-) drugs, summed across their latest reported year of disclosures. Payments include both general and research categories; see methodology for the split.
| Manufacturer | Total disclosed to oncologists (latest year) |
|---|---|
| AstraZeneca | $11,913,894 |
| Pfizer | $8,033,132 |
| Eli Lilly | $6,269,708 |
| Gilead | $3,438,640 |
| Daiichi Sankyo | $3,153,149 |
| Novartis | $2,644,139 |
| Stemline Therapeutics (Menarini) | $1,044,475 |
breast cancer (hr+/her2-) trials with research-payment cross-reference
Active breast cancer (hr+/her2-) trials in our database where one or more research-payment records (tied to the trial's NCT ID) are disclosed in CMS Open Payments. We show the disclosed principal investigators and amounts. The presence of research payments on a trial is expected — industry-funded clinical trials pay the physicians running them for site work — but knowing the scale gives you useful context.
Sponsor: BeOne Medicines
Disclosed research payments
$1,175,163
Named PIs
4
- TIMOTHY YAP: $638,552
- GERALD FALCHOOK: $450,883
- ILDEFONSO RODRIGUEZ RIVERA: $49,381
Sponsor: Daiichi Sankyo · sponsor also appears in the payment records
Disclosed research payments
$974,118
Named PIs
3
- DAVID BERZ: $834,302
- JAMES D OLIMPIO: $114,421
- IRA OLIFF: $25,395
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Sponsor: Eli Lilly and Company · sponsor also appears in the payment records
Disclosed research payments
$427,568
Named PIs
5
- ALEXANDER WEI: $85,059
- XIN GAO: $80,359
- MATTHEW GALSKY: $79,328
Questions to ask your oncologist
- Among the approved options for my stage and biomarker profile, which do you recommend, and why this one over its close substitutes?
- Have you received consulting, speaking, or research payments from the maker of the drug you're recommending? (Every U.S. physician can look themselves up at openpaymentsdata.cms.gov.)
- Are there cooperative-group or NIH-sponsored trials I should consider, in addition to industry-sponsored ones?
- What do the published head-to-head trials show for the option you're recommending versus its substitutes?
A financial relationship between a physician and a manufacturer is not, on its own, a problem — it is the expected context of modern drug development. The purpose of federal disclosure is to let you ask informed questions, not to make the decision for you.
More on breast cancer (hr+/her2-)
Medical disclaimer: This page aggregates public federal data and is not medical advice. Drug choice for any individual patient depends on stage, biomarker profile, prior therapy, comorbidities, and patient preference — decisions that must be made with your licensed care team.
About the payment data: Figures are disclosed by manufacturers to CMS under the Physician Payments Sunshine Act (42 U.S.C. §1320a-7h). Presence of payments is not a conflict of interest. Physicians who believe a record is wrong file a correction through the CMS dispute process.
Sources: CMS Open Payments · ClinicalTrials.gov · Data fetched: 2026-04-21 · full methodology